297 related articles for article (PubMed ID: 32861288)
61. MDCT of extranodal mantle cell lymphoma: a single institute experience.
Baheti AD; Tirumani SH; Sewatkar R; Sachin SS; Shinagare AB; Ramaiya NH
Abdom Imaging; 2015 Aug; 40(6):1693-9. PubMed ID: 25724714
[TBL] [Abstract][Full Text] [Related]
62. Accuracy of diagnosing mantle cell lymphoma and identifying its variants on fine-needle aspiration biopsy.
Foshat M; Stewart J; Khoury JD; Staerkel GA; Caraway NP
Cancer Cytopathol; 2019 Feb; 127(1):44-51. PubMed ID: 30452126
[TBL] [Abstract][Full Text] [Related]
63. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.
Narkhede M; Goyal G; Shea L; Mehta A; Giri S
Blood Adv; 2022 Jul; 6(14):4122-4131. PubMed ID: 35561314
[TBL] [Abstract][Full Text] [Related]
64. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
65. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma.
Choe JY; Yun JY; Na HY; Huh J; Shin SJ; Kim HJ; Paik JH; Kim YA; Nam SJ; Jeon YK; Park G; Kim JE
Histopathology; 2016 Feb; 68(3):442-9. PubMed ID: 26100211
[TBL] [Abstract][Full Text] [Related]
66. Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features.
Khanlari M; Mo H; Kim DH; Sakhdari A; Young KH; Jain P; Wang M; Li S; Kanagal-Shamanna R; Miranda RN; Vega F; Medeiros LJ; Ok CY
Am J Surg Pathol; 2023 Aug; 47(8):849-858. PubMed ID: 37288826
[TBL] [Abstract][Full Text] [Related]
67. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
[TBL] [Abstract][Full Text] [Related]
68. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.
Zeng W; Fu K; Quintanilla-Fend L; Lim M; Ondrejka S; Hsi ED
Am J Surg Pathol; 2012 Feb; 36(2):214-9. PubMed ID: 22251940
[TBL] [Abstract][Full Text] [Related]
69. Deep Learning-Based Nuclear Morphometry Reveals an Independent Prognostic Factor in Mantle Cell Lymphoma.
Chuang WY; Yu WH; Lee YC; Zhang QY; Chang H; Shih LY; Yeh CJ; Lin SM; Chang SH; Ueng SH; Wang TH; Hsueh C; Kuo CF; Chuang SS; Yeh CY
Am J Pathol; 2022 Dec; 192(12):1763-1778. PubMed ID: 36150505
[TBL] [Abstract][Full Text] [Related]
70. Bilateral ocular panadnexal mass as initial presentation of systemic blastoid variant of mantle-cell lymphoma.
Rašić DM; Knežević M; Terzić T; Vlajković G
Surv Ophthalmol; 2017; 62(1):83-88. PubMed ID: 27256688
[TBL] [Abstract][Full Text] [Related]
71. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
[TBL] [Abstract][Full Text] [Related]
72. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
Hoster E; Rosenwald A; Berger F; Bernd HW; Hartmann S; Loddenkemper C; Barth TF; Brousse N; Pileri S; Rymkiewicz G; Kodet R; Stilgenbauer S; Forstpointner R; Thieblemont C; Hallek M; Coiffier B; Vehling-Kaiser U; Bouabdallah R; Kanz L; Pfreundschuh M; Schmidt C; Ribrag V; Hiddemann W; Unterhalt M; Kluin-Nelemans JC; Hermine O; Dreyling MH; Klapper W
J Clin Oncol; 2016 Apr; 34(12):1386-94. PubMed ID: 26926679
[TBL] [Abstract][Full Text] [Related]
73. Blastoid Variant of Mantle Cell Lymphoma with Extranodal Presentation and Aberrant CD10 Expression.
Raman A; Jinkala SR; Murugan R; Manivannan P
Int J Appl Basic Med Res; 2024; 14(1):63-66. PubMed ID: 38504844
[TBL] [Abstract][Full Text] [Related]
74. Therapeutic options for relapsed/refractory mantle cell lymphoma.
Eyre TA; Cheah CY; Wang ML
Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
[TBL] [Abstract][Full Text] [Related]
75. Mantle cell lymphoma with skin invasion characterized by the common variant in the subcutis and blastoid transformation in the overlying dermis.
Ishibashi M; Yamamoto K; Kudo S; Chen KR
Am J Dermatopathol; 2010 Apr; 32(2):180-2. PubMed ID: 20010283
[TBL] [Abstract][Full Text] [Related]
76. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L; Malpica L; Tummala S; Flowers C; Neelapu SS; Wang ML; Jain P
Leuk Lymphoma; 2024 May; 65(5):669-673. PubMed ID: 38248629
[No Abstract] [Full Text] [Related]
77. Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation.
Aurer I
Curr Opin Oncol; 2019 Sep; 31(5):374-379. PubMed ID: 31233483
[TBL] [Abstract][Full Text] [Related]
78. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
Tbakhi B; Reagan PM
Ther Adv Hematol; 2022; 13():20406207221080738. PubMed ID: 35237395
[TBL] [Abstract][Full Text] [Related]
79. Large-cell variants of mantle cell lymphoma: cytologic characteristics and p53 anomalies may predict poor outcome.
Zoldan MC; Inghirami G; Masuda Y; Vandekerckhove F; Raphael B; Amorosi E; Hymes K; Frizzera G
Br J Haematol; 1996 May; 93(2):475-86. PubMed ID: 8639452
[TBL] [Abstract][Full Text] [Related]
80. Extranodal Head and Neck Mantle Cell Lymphoma: Characteristics, Treatment, and Survival.
Breen CT; Chao J; Mehra S; Kohli N
Ann Otol Rhinol Laryngol; 2022 Apr; 131(4):412-419. PubMed ID: 34137303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
